

Cornelia Schuster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8457408/publications.pdf>

Version: 2024-02-01

11
papers

128
citations

1478505

6
h-index

1720034

7
g-index

12
all docs

12
docs citations

12
times ranked

246
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. <i>International Journal of Cancer</i> , 2022, 150, 100-111. | 5.1 | 11 |
| 2 | ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. <i>Scientific Reports</i> , 2019, 9, 17471. | 3.3 | 26 |
| 3 | Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. <i>PLoS ONE</i> , 2019, 14, e0210399. | 2.5 | 20 |
| 4 | Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 53-62. | 3.0 | 7 |
| 5 | A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9548-9548. | 1.6 | 3 |
| 6 | The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. , 2017, , 481-506. | | 0 |
| 7 | Abstract CT056: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma. , 2017, , . | | 0 |
| 8 | Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study. <i>PLoS ONE</i> , 2016, 11, e0155242. | 2.5 | 15 |
| 9 | Abstract 2828: High expression of heat shock protein 27 in metastases is correlated with response to bevacizumab monotherapy in patients with metastatic melanoma. , 2014, , . | | 0 |
| 10 | Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension. <i>PLoS ONE</i> , 2012, 7, e38364. | 2.5 | 46 |
| 11 | Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study. , 2012, , . | | 0 |